These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 22728007)

  • 1. [Targeted therapy and breast cancer: state of the art].
    Molnar-Stanciu D; Guimas V; Bensalem A; Thiery-Vuillemin A
    Pathol Biol (Paris); 2012 Aug; 60(4):254-63. PubMed ID: 22728007
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Blockade of the HER family of receptors in the treatment of HER2-positive metastatic breast cancer.
    Sachdev JC; Jahanzeb M
    Clin Breast Cancer; 2012 Feb; 12(1):19-29. PubMed ID: 21903480
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ErbB family receptor inhibitors as therapeutic agents in breast cancer: current status and future clinical perspective.
    Saxena R; Dwivedi A
    Med Res Rev; 2012 Jan; 32(1):166-215. PubMed ID: 22183797
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Integration of novel targeted therapies into the systemic treatment of breast cancer--a review.
    Tsakonas G; Kosmas C
    J BUON; 2007; 12(3):319-27. PubMed ID: 17918284
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evolving strategies for overcoming resistance to HER2-directed therapy: targeting the PI3K/Akt/mTOR pathway.
    Nahta R; O'Regan RM
    Clin Breast Cancer; 2010 Nov; 10 Suppl 3():S72-8. PubMed ID: 21115425
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Her2-positive breast cancer: herceptin and beyond.
    Dean-Colomb W; Esteva FJ
    Eur J Cancer; 2008 Dec; 44(18):2806-12. PubMed ID: 19022660
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Strategies of breast cancer treatment based on determination of biological subtype].
    Semiglazov VF
    Vopr Onkol; 2011; 57(5):542-52. PubMed ID: 22238922
    [No Abstract]   [Full Text] [Related]  

  • 8. Emerging targeted therapies for breast cancer.
    Alvarez RH; Valero V; Hortobagyi GN
    J Clin Oncol; 2010 Jul; 28(20):3366-79. PubMed ID: 20530283
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New drugs for breast cancer.
    Tookman L; Roylance R
    Br Med Bull; 2010; 96():111-29. PubMed ID: 20870669
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Predictive value of Her2/neu expression/amplification for the targeted treatment of breast cancer].
    Lehr HA; Schaefer SC; Delaloye JF
    Rev Med Suisse; 2009 Jul; 5(211):1525-9. PubMed ID: 19694364
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [News in the medical treatment of breast cancer].
    Piccart M; Dochy E; Cardoso F
    Bull Cancer; 2003 Jan; 90(1):46-52. PubMed ID: 12609804
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Target-based therapies in breast cancer: current status and future perspectives.
    Normanno N; Morabito A; De Luca A; Piccirillo MC; Gallo M; Maiello MR; Perrone F
    Endocr Relat Cancer; 2009 Sep; 16(3):675-702. PubMed ID: 19525314
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Mechanisms of resistance to molecular targeted therapies in breast cancer: update and future].
    Magné N; Chargari C; Conforti R; Toillon RA; Bauduceau O; Védrine L; Khayat D; Spano JP
    Bull Cancer; 2010 Mar; 97(3):385-95. PubMed ID: 20167563
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HER2 as a target for breast cancer therapy.
    Tagliabue E; Balsari A; Campiglio M; Pupa SM
    Expert Opin Biol Ther; 2010 May; 10(5):711-24. PubMed ID: 20214497
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lapatinib: new directions in HER2 directed therapy for early stage breast cancer.
    Jo Chien A; Rugo HS
    Cancer Treat Res; 2009; 151():197-215. PubMed ID: 19593514
    [No Abstract]   [Full Text] [Related]  

  • 16. HER2-positive breast cancer: from trastuzumab to innovatory anti-HER2 strategies.
    Whenham N; D'Hondt V; Piccart MJ
    Clin Breast Cancer; 2008 Feb; 8(1):38-49. PubMed ID: 18501058
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer.
    Nahta R; Yu D; Hung MC; Hortobagyi GN; Esteva FJ
    Nat Clin Pract Oncol; 2006 May; 3(5):269-80. PubMed ID: 16683005
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Human recombinant anti-HER2 monoclonal antibody--a new targeted treatment in breast cancer].
    Dank M
    Orv Hetil; 2001 Nov; 142(46):2563-8. PubMed ID: 11770175
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Trastuzumab (herceptin) for the medical treatment of breast cancer].
    Bayoudh L; Afrit M; Daldoul O; Zarrad M; Boussen H
    Tunis Med; 2012 Jan; 90(1):6-12. PubMed ID: 22311450
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mechanisms of resistance to HER2 target therapy.
    Tortora G
    J Natl Cancer Inst Monogr; 2011; 2011(43):95-8. PubMed ID: 22043051
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.